Calendario›MGNX›MGC030
MGC030
A Study of MGC030 in Participants With Advanced Solid Tumors
Ensayo de MACROGENICS INC en Urothelial Cancer · GastroEsophageal Cancer · Colorectal Cancer · Esophageal Cancer · Gastric Cancer (GC) · Pancreatic Cancer (del registro, en inglés).
Más ensayos de: Cáncer colorrectal · Cáncer de esófago · Cáncer de páncreas.
- Fase
- Fase 1
- Estado
- Aún sin reclutar
- Participantes
- 314
- Fin del objetivo primario
- sep 2028
Qué significa cada fase y cada estado.
Estudio de intervención, no aleatorizado, abierto. Comenzó en sep 2026.
Qué mide
Number of participants with adverse events (AEs), serious AEs (SAEs), AEs leading to dose interruption, AEs leading to dose reduction or treatment discontinuation, does limiting toxicities and AEs of special interest. (Throughout the study, estimated duration 2 years.) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of MGC030. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors of select types. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC030? * Can MGC030 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors? Participants will * Undergo screening procedures to determine eligibility * Receive study treatments initially every 3 weeks. * Have blood samples taken for routine and research tests * Have other examinations to check heart and lung function, and general health status * Be asked about any side effects that may be happening or other medications you are taking. The study doctor will provide treatment for side effects, if necessary. * Have the study doctor assess your tumor status at regular intervals to determine how you are responding to treatment.
Más ensayos de MGNX
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| MGC028 | Fase 1 | Reclutando pacientes | nov 2026 (prevista) |
| MGD024 | Fase 1 | En marcha, sin reclutar | nov 2026 (prevista) |
| Lorigerlimab | Fase 2 | Reclutando pacientes | jul 2027 (prevista) |
| MGC026 Dose Escalation | Fase 1 | Reclutando pacientes | may 2028 (prevista) |
| lorigerlimab | Fase 2 | Completado | feb 2026 (real) |
| vobramitamab duocarmazine | Fase 1 | Completado | jun 2025 (real) |
Todos los de MGNX, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT07822399), actualizada en sep 2026.